MaxCyte begins dosing in phase I solid tumors clinical trial

MaxCyte has dosed the first patient in its US phase I dose-escalation clinical trial of chimeric antigen receptor (CAR) therapeutic candidate, MCY-M11. The study is designed to evaluate MCY-M11, a mesothelin targeting CAR, in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma.